Empowering Health Innovation with Capital, Strategy, and Global Networks.
Investing in breakthrough technologies to drive global health advancements.
To accelerate the development of emerging medical technologies with robust financial backing, commercialization expertise, and expansive global networking opportunities.
About Us
At Medmine Partners, we are dedicated to advancing healthcare delivery by supporting innovative companies that are at the forefront of medical and biotechnological breakthroughs. Based in Australia, our team combines deep industry knowledge with global insights to drive economic competitiveness and transformation.
Our Mission
Our Services
-
We invest in tomorrow. With a keen eye on transformative potential, MedMine Partners provides the capital necessary to scale groundbreaking technologies from concept to market.
Financing Breakthrough Innovations
Access to a Global Network of Investors
Unique Opportunities for Co-investments
-
Strategically navigating global markets, we provide bespoke, tailored commercialization strategies that advance your innovations from concept to impactful success, maximizing both local and international opportunities.
Navigating the Regulatory Process
Reimbursement Assessments and Coding Strategy
Patents & Licensing
Market Access
Clinical Access and Market Adoption
-
Our extensive global network opens doors to key partnerships, collaborative opportunities, and market expansions, positioning your technology on the world stage.
Global Markets Outreach: Expertise in Accessing Target Markets for Medical Sciences
Fast Track Global Expansion
Cross Industry Collaborations
Why MedMine Partners?
MedMine Partners plays a pivotal role in elevating Australia’s commercialization success on the global stage.
We are dedicated to transforming the life sciences sector by selecting and nurturing best-in-class innovations, ensuring they not only excel in markets but also redefine standards of healthcare efficacy and accessibility.
Innovation Portfolio
Medical devices
New MedTek Devices Pty Ltd is an early-stage medical device company collaborating with surgical professionals to uncover and develop the next generation of patient-focused technologies.
Digital health
Medow Health empowers Specialists to deliver superior patient care whilst improving practice efficiency.
Digital health
Medbill empowers businesses with cutting-edge billing solutions and software, driving operational efficiency and financial success.
Testimonials
-
“Since meeting Gary and the MedMine Partners team, I’ve been deeply impressed by their unwavering support and strategic insight. They don’t just assist when asked; they’re proactive, regularly reaching out with new ideas, valuable connections, and meaningful guidance. Their deep experience in medtech, combined with extensive partnerships within the ecosystem, is incredibly valuable for any healthtech founder. I highly recommend Gary and the entire MedMine Partners team to anyone looking for a truly supportive and insightful investment partner.”
Joel Freiberg,
Medow Health Founder
-
"The MedMine Partners team has been a supportive and incredibly valuable partner for us. Their knowledge and connections within the healthcare industry have been instrumental in setting us up for success. Whether through customer introductions, strategic partnerships, or industry insights, the entire MedMine Partners team has leaned in and assisted whenever needed. I couldn’t recommend the team more highly to any founder looking for a value-add partner and investor.”
John Austin,
Medbill Founder
The Team
Gary Zamel
Gary Zamel is a serial entrepreneur with over 35 years of experience in investing in, scaling, and successfully exiting medical technology and other companies.
With an extensive network across the research, product development, technology, commercial and managerial arenas, and strong connections with a broad pool of sophisticated investors, Gary is able to form cohesive teams to meet the differing timeline needs of bringing products to market.
Gary advises MTAA on strengthening Australian Life Sciences capabilities and offers strategic counsel to UNSW's medical precinct. He is a Fellow of the Australian Academy of Technology Science and Engineering and an Honorary Fellow at Engineers Australia.
Leslie Butterfield
Leslie Butterfield brings over 20 years of experience as a Non-Executive Director and 14 years as Chief Executive and Regional Managing Director of a multinational professional services firm.
She excels in simplifying strategies and defining clear paths forward, with expertise in scaling businesses, managing program rollouts, and leveraging technology platforms.
Leslie is recognized for developing innovative service delivery methodologies that drive growth, success, and long-term sustainability.
Professor David Lubowski AM
Professor David Lubowski AM is a leader in colorectal surgery, serving as Conjoint Professor at UNSW and Head of Colorectal Surgery at St George Hospital, Sydney.
Recognized with the Order of Australia, he has published over 120 articles and 21 textbook chapters, contributing significantly to the field.
He is a visiting professor and an entrepreneur who has commercialized drugs and devices now standard in global care.
With a Google Scholar h-Index of 50 and over 7,400 citations, his impact on colorectal surgery is profound and enduring.
Joshua Gunn, Ph.D.
Dr. Joshua Gunn is a chief scientist with over 15 years of experience in diagnostics, specializing in the development and commercialization of novel technologies.
He is adept at navigating coding, coverage, and reimbursement complexities to ensure successful market entry and clinical adoption.
Josh is passionate about improving patient outcomes through cost-effective, innovative technologies.
He excels in leading multidisciplinary teams, forging partnerships with regulatory bodies, and ensuring that new technologies meet rigorous clinical and economic standards, ultimately advancing patient care.
Contact Us
Join us in shaping the future of healthcare. Contact Medmine Partners to discover how your innovation can contribute to technological sovereignty and global health advancements.